Nuformix plc (NFX) - Total Liabilities
Based on the latest financial reports, Nuformix plc (NFX) has total liabilities worth GBX263.92K GBX (≈ $32.11 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Nuformix plc to assess how effectively this company generates cash.
Nuformix plc - Total Liabilities Trend (2014–2025)
This chart illustrates how Nuformix plc's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Nuformix plc for net asset value and shareholders' equity analysis.
Nuformix plc Competitors by Total Liabilities
The table below lists competitors of Nuformix plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Macau Property Opportunities Fund Ltd
LSE:MPO
|
UK | GBX47.78 Million |
|
MSP Recovery Inc
NASDAQ:MSPR
|
USA | $2.40 Billion |
|
Athelney Trust plc
LSE:ATY
|
UK | GBX27.22K |
|
Aditxt Inc.
NASDAQ:ADTX
|
USA | $20.66 Million |
|
S&W Seed Company
NASDAQ:SANW
|
USA | $42.79 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Nuformix plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nuformix plc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nuformix plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nuformix plc (2014–2025)
The table below shows the annual total liabilities of Nuformix plc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | GBX263.92K ≈ $32.11 |
+3.51% |
| 2024-09-30 | GBX254.97K ≈ $31.02 |
+14.34% |
| 2023-09-30 | GBX222.99K ≈ $27.13 |
-18.48% |
| 2023-03-31 | GBX273.56K ≈ $33.28 |
+15.01% |
| 2022-03-31 | GBX237.86K ≈ $28.94 |
-26.73% |
| 2021-03-31 | GBX324.62K ≈ $39.50 |
-15.44% |
| 2020-03-31 | GBX383.91K ≈ $46.71 |
-53.15% |
| 2019-03-31 | GBX819.52K ≈ $99.71 |
+53.47% |
| 2018-03-31 | GBX534.00K ≈ $64.97 |
+168.05% |
| 2017-03-31 | GBX199.21K ≈ $24.24 |
+369.28% |
| 2016-03-31 | GBX42.45K ≈ $5.17 |
-39.15% |
| 2015-12-31 | GBX69.76K ≈ $8.49 |
-82.20% |
| 2015-07-31 | GBX391.86K ≈ $47.68 |
+36.41% |
| 2014-07-31 | GBX287.26K ≈ $34.95 |
-- |
About Nuformix plc
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more